TENX Tenax Therapeutics Inc.

1.16
+0.02  (+2%)
Previous Close 1.14
Open 1.15
Price To Book 0.7
Market Cap 7,184,146
Shares 6,193,229
Volume 65,197
Short Ratio
Av. Daily Volume 88,180

NewsSee all news

  1. What Kind Of Investor Owns Most Of Tenax Therapeutics, Inc. (NASDAQ:TENX)?
  2. TENX: Screening & Enrollment Continue
  3. TENX: HELP Trial Enrollment Underway
  4. Introducing Tenax Therapeutics (NASDAQ:TENX), The Stock That Collapsed 98%
  5. Tenax Therapeutics Enrolls First Patient for Phase 2 Pulmonary Hypertension Clinical Trial

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 enrolment to continue through 2019.
Levosimendan
Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF)
Phase 2b trial did not meet primary endpoint.
Levosimendan
Septic shock
Phase 3 top line data released January 31, 2017 - primary endpoints not met. Met with FDA May 10, 2017 to discuss potential NDA submission.
Levosimendan
Reduce the incidence of low cardiac output syndrome during cardiac surgery

Latest News

  1. What Kind Of Investor Owns Most Of Tenax Therapeutics, Inc. (NASDAQ:TENX)?
  2. TENX: Screening & Enrollment Continue
  3. TENX: HELP Trial Enrollment Underway
  4. Introducing Tenax Therapeutics (NASDAQ:TENX), The Stock That Collapsed 98%
  5. Tenax Therapeutics Enrolls First Patient for Phase 2 Pulmonary Hypertension Clinical Trial
  6. Four Biotech Stocks Setting The Standard On Thursday (2/21/19)
  7. Tenax Therapeutics to Present at 2019 BIO CEO & Investor Conference
  8. Tenax Therapeutics to Present at Biotech Showcase Investor Conference
  9. Tenax Therapeutics Announces Closing of $10 Million Underwritten Offering
  10. Tenax Therapeutics Announces Pricing of $10 Million Underwritten Offering
  11. TENX: We Have Liftoff: HELP Site Activated
  12. Heat Biologics Takes Beating After Pricing $12 Million Stock Offering
  13. Tenax Therapeutics Activates First Clinical Research Site for Phase 2 Pulmonary Hypertension Clinical Trial
  14. TENX: Tenax S-1 Filing
  15. How Should You Think About Tenax Therapeutics Inc’s (NASDAQ:TENX) Risks?
  16. Tenax Therapeutics to Present at Upcoming Investor Conferences
  17. TENX: 3Q Start to Pulmonary Hypertension Trial